Efficacy of mirabegron in patients with overactive bladder (OAB): Pre-specified analysis of three randomised, double-blind, placebo-controlled, Phase III studies

Nitti V1, Herschorn S2, Khullar V3, Cambronero J4, Angulo J5, Blauwet M B6, Dorrepaal C7, Siddiqui E8, van Kerrebroeck P9, Martin N10

Abstract Category

Detrusor Overactivity

Abstract 222
LUTS Evaluation and Treatment
Scientific Podium Poster Session 24
Friday 19th October 2012
14:25 - 14:30
1. NYU Langone Medical Center, Department of Urology, New York, NY, USA, 2. University of Toronto, Division of Urology, Toronto, ON, Canada, 3. St Mary’s Hospital, Imperial College, Urogynaecology Department, London, UK, 4. Infanta Leonor Hospital, Department of Urology, Madrid, Spain, 5. Hospital Universitario De Getafe, Department of Urology, Madrid, Spain, 6. Astellas Pharma Global Development, Inc., Global Data Science – Biostatistics, Deerfield, IL, USA, 7. Astellas Pharma Global Development – EU, Global Medical Science – Urology, Leiderdorp, The Netherlands, 8. Astellas Pharma Europe Ltd, Staines, Middlesex, UK, 9. Department of Urology, Maastricht University Medical Center, The Netherlands, 10. Astellas Scientific and Medical Affairs Inc, Deerfield, IL, USA
Presenter
S

Sender Herschorn

Links

Abstract